CT is specialized in cancer immunotherapies and antibody-drug conjugates for the treatment of solid tumor. CT has developed innovative technologies to generate NK cell-based targeted immunotherapies
CT's platform allows engineering of NK cells into targeted chemoimmunotherapy for various cancers
Welcome and Thank you for your interest in Partnering with us.
We would like to invite you to have a look at our Technology.
We are open to further discussion.
Thanks for submitting!